Essex Woodlands Management, Inc. Revance Therapeutics, Inc. Transaction History
Essex Woodlands Management, Inc.
- $349 Million
- Q3 2024
A detailed history of Essex Woodlands Management, Inc. transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Essex Woodlands Management, Inc. holds 457,085 shares of RVNC stock, worth $1.17 Million. This represents 0.34% of its overall portfolio holdings.
Number of Shares
457,085
Previous 457,085
-0.0%
Holding current value
$1.17 Million
Previous $1.17 Million
-0.0%
% of portfolio
0.34%
Previous 0.38%
Shares
7 transactions
Others Institutions Holding RVNC
# of Institutions
223Shares Held
80.5MCall Options Held
706KPut Options Held
882K-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.63MShares$14.5 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA4.78MShares$12.3 Million0.0% of portfolio
-
Fil LTD Hamilton, D04.19MShares$10.8 Million0.01% of portfolio
-
Alliancebernstein L.P. New York, NY3.26MShares$8.38 Million0.0% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...